μ-opioid receptor

μ-opioid receptor. The μ-opioid receptor (MOR) is a G protein-coupled receptor that is the principal molecular target for most clinically used opioid analgesics, including morphine, fentanyl, and oxycodone. Its activation in the central nervous system and peripheral nervous system mediates profound analgesia, euphoria, and respiratory depression, which are central to both therapeutic effects and the risks of opioid use disorder. The receptor is encoded by the OPRM1 gene in humans and is a critical component of the body's endogenous pain modulation pathways, interacting with peptides like β-endorphin.

Structure and function

The μ-opioid receptor is a member of the Class A Rhodopsin-like family of G protein-coupled receptors, characterized by seven transmembrane domains. Its intracellular loops, particularly the second and third, are crucial for coupling to inhibitory G_i/o protein subtypes. Upon activation by an agonist, the receptor initiates a signaling cascade that inhibits adenylyl cyclase activity, reduces cyclic AMP production, and promotes the opening of potassium channels while inhibiting voltage-gated calcium channels. This hyperpolarizes neurons, predominantly in regions like the periaqueductal gray, rostral ventromedial medulla, and spinal cord dorsal horn, leading to reduced neurotransmitter release and diminished pain signal transmission. The receptor also engages β-arrestin pathways, which are implicated in side effects like constipation and respiratory depression.

Gene and expression

The human μ-opioid receptor is encoded by the OPRM1 gene located on chromosome 6 at locus 6q25.2. The gene undergoes extensive alternative splicing, producing numerous mRNA variants that translate into receptor isoforms with potentially distinct pharmacological properties and tissue distributions. Expression is highest in the brain, particularly within the cerebral cortex, thalamus, striatum, and hippocampus, as well as in key pain-modulation centers like the periaqueductal gray. It is also found in the gastrointestinal tract, immune cells, and sensory neurons of the dorsal root ganglion. Polymorphisms in the OPRM1 gene, such as the common A118G single-nucleotide polymorphism, have been studied for their association with variability in opioid response and susceptibility to addiction.

Ligands and pharmacology

Ligands for the μ-opioid receptor are classified as full agonists, partial agonists, or antagonists based on their intrinsic activity. Endogenous ligands include the opioid peptides β-endorphin, enkephalin, and endomorphin. Exogenous full agonists encompass most therapeutic opioids, such as morphine, hydromorphone, oxycodone, and the potent synthetic agent fentanyl. The partial agonist buprenorphine is used in medication-assisted treatment for opioid use disorder, while pure antagonists like naloxone and naltrexone block the receptor and are essential for reversing opioid overdose and managing dependence. The receptor's pharmacology is complex, with ligands exhibiting different signaling bias toward G protein versus β-arrestin pathways, a key area of modern drug development aimed at separating analgesia from adverse effects.

Clinical significance

The μ-opioid receptor is the primary target for managing moderate to severe acute pain and cancer pain, making agonists like morphine a cornerstone of palliative care and anesthesiology. However, prolonged activation leads to tolerance, physical dependence, and opioid use disorder, a major public health crisis often involving drugs like heroin and oxycodone. The life-threatening side effect of respiratory depression is mediated by this receptor in the brainstem. Conversely, antagonists such as naloxone are frontline treatments for opioid overdose. Research into biased agonists that preferentially activate G protein signaling aims to develop safer analgesics with less respiratory depression and constipation.

Research history

The existence of opioid receptors was hypothesized following the work of pharmacologists like Alfred G. Gilman and the discovery of endogenous opioids by John Hughes and Hans Kosterlitz in the 1970s. The μ-opioid receptor was first definitively identified and cloned in 1993 by teams led by Chris Evans and Brigitte Kieffer, a breakthrough that allowed detailed molecular study. Pioneering work by Candace Pert and Solomon Snyder earlier provided crucial evidence for receptor binding sites in the brain. Subsequent research, including studies by Laura Bohn on β-arrestin signaling, has refined understanding of receptor function. The cloning of OPRM1 enabled the generation of knockout mouse models, which confirmed the receptor's essential role in morphine-induced analgesia and reward.

Category:G protein-coupled receptors Category:Opioid receptors Category:Analgesics